NCT05053165已完成1 期
A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of LB-P6 or LB-P8 in Healthy Participants
LISCure Biosciences1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2022年1月4日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- To assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants through adverse events as assessed by NCI-CTCAE v5.0
研究概览
简要总结
The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.
详细描述
This is randomised, double-blind, placebo-controlled, single centre study to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.
A total of up to 30 healthy participants will be enrolled in 2 cohorts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female, aged 18 to 65 years (inclusive at the time of consent).
- •BMI ≥ 18 to ≤ 32 kg/m2 and with weight ≥ 50 kg at Screening.
- •Must have a negative urine drug screen at the Screening Visit and the day before dosing (Day -1); one repeat urine drug may be conducted for a suspected false positive result.
- •Female participants should meet 1 of the following criteria before they can participate in the study:
- •Not of childbearing potential, defined as surgically sterile for at least 12 months prior to screening or postmenopausal
- •Of childbearing potential and agrees to take effective contraceptive measures throughout the study period from study entry (ie, screening) until at least 3 months after the last dose of IP.
- •Of childbearing potential and in an exclusive relationship with a partner who has had a bilateral vasectomy at least 6 months prior to study entry.
- •Female participant of childbearing potential must have a negative serum pregnancy test at Screening, and a negative urine pregnancy test at Baseline (ie, Day -1), and be willing to have additional pregnancy tests, as required, throughout the study, at the discretion of the PI or designee.
- •Male participant: has undergone bilateral vasectomy (at least 6 months prior to study entry) or agrees to use effective contraceptive measures and not donate sperm throughout the study period from study entry (ie, Screening) until at least 3 months after the last dose of IP.
- •Must agree to adhere to the current state and national advice regarding minimising exposure to COVID-19 from the first Screening Visit until the EOS Visit.
排除标准
- •Female participants who are pregnant, lactating, or who plan to become pregnant within 90 days of the EOS Visit.
- •The participant has either a history or presence of any clinically significant immunological disorder/disease (such as autoimmune diseases, etc.), cardiovascular, thromboembolic events, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological (particularly diabetes or prediabetes), haematological, dermatological, venereal, neurological, chronic infectious or psychiatric disease or other major disorder that, in the opinion of the PI or designee, may interfere with trial compliance, completion, or accurate assessment of trial outcomes or safety.
- •The participant has taken prescription (including antibiotics and anti-virals) or non prescription medication, herbal remedies, vitamins or minerals, any probiotics and yeast supplements within 14 days prior to the first dose of IP unless in the opinion of the PI or designee the medication will not compromise participant safety or interfere with study procedures or data validity. Participants may be rescreened after a washout period of 14 days. Use of contraceptives and paracetamol up to 2 g/day and/or nonsteroidal anti inflammatory drugs (NSAIDs) for symptomatic relief of minor symptoms are allowed.
- •The participant has a substance abuse-related disorder or has a history of drug, alcohol, and/or substance abuse deemed significant by the PI or designee. Any participant with a positive screen for drugs of abuse or alcohol at Screening or on Day -1 will also be excluded.
- •The participant has taken any IPs within 30 days prior to the first dose of IP or 5 half-lives, whichever is longer.
- •Positive test result for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus antibody (anti-HCV), FOB at Screening.
- •The participant has a fever (body temperature > 38°C) or symptomatic viral or bacterial infection within 2 weeks prior to admission to the clinical research unit (CRU).
- •The participant has undergone vaccination (including with a live-attenuated vaccine) within 30 days prior to Baseline (Day -1) through to the end of the study.
研究组 & 干预措施
A (LB-P6)
Experimental
Healthy volunteers will be administered once daily orally
干预措施: LB-P6 (Drug)
B (LB-P8)
Experimental
Healthy volunteers will be administered once daily orally
干预措施: LB-P8 (Drug)
C (Placebo)
Experimental
Healthy volunteers will be administered once daily orally
干预措施: Placebo (Drug)
结局指标
主要结局
To assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants through adverse events as assessed by NCI-CTCAE v5.0
时间窗: Measurements at Baseline till 14 days after the last dose of study drug
Number of participants with treatment related adverse events as assessed by NCI-CTCAE v5.0
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult SubjectsHealthyNCT00956956Pfizer36
已完成
1 期
A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1Myotonic Dystrophy Type 1NCT02312011Ionis Pharmaceuticals, Inc.48
招募中
1 期
A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383CoughNCT06092983Jiangsu Hansoh Pharmaceutical Co., Ltd.48
已完成
1 期
Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With SchizophreniaSchizophreniaNCT01457339Shire31
已完成
1 期
A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult SubjectsHealthyNCT01140672Pfizer48